MedPath

Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia

Recruiting
Conditions
Arbovirus Infections
Dengue
Zika
Chikungunya
Registration Number
NCT04615364
Lead Sponsor
Institut Pasteur
Brief Summary

Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, especially in tropical and sub-tropical countries. A promising strategy aimed at blocking the circulation of arboviruses is to release Aedes aegypti mosquitoes carrying the endosymbiotic bacterium Wolbachia. In 2019, the Wolbachia strategy was implemented in Nouméa as part of the World Mosquito Program. This intervention will modify the epidemiological profile of arboviruses in New Caledonia.

Epidemiological surveillance of arboviruses requires molecular characterization of the virus contained in the serum obtained from the blood collected from patients. This molecular characterization by RNA isolation techniques, RT-qPCR monitoring and sequencing allows the construction of phylogenetic trees.

In the context of the implementation of the World Mosquito Program in Nouméa, the investigators plan to follow the molecular evolution of arboviruses, over the period preceding the releases of mosquitoes carrying Wolbachia (from 1995 to 2019) then over a period of 5 years. following the releases.

At the same time, the virus can be isolated by cell culture techniques and in vitro infections, allowing its study in vitro in cells or in vivo in mosquitoes. This study allows us to measure the impact of the Wolbachia strategy on the evolution of the virus's ability to replicate in cells in the presence of Wolbachia and to be transmitted by the mosquito.

Detailed Description

Collection of blood samples from patients with arbovirus infection

This study is a non-interventional study with retrospective part.

This study will improve :

* the assessment of the molecular evolution of arboviruses in the period preceding the implementation of the Wolbachia strategy

* the knowledge of the impact of Wolbachia on the diversity and molecular evolution of arboviruses

* the understanding of arbovirus transmission and replication mechanisms in the presence of Wolbachia

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
600
Inclusion Criteria
  • Appearance of clinical signs suggestive of an infection with an arbovirus in the 7 days preceding the blood sample,
  • Diagnostic confirmation by RT-qPCR of mono-infection with dengue virus or another arbovirus.
  • Patients or their representative (s) informed of the possible secondary use for research purposes of the samples initially taken for diagnostic purposes and their derivatives, and who have not since expressed their opposition to the secondary use of the samples diagnostics or their derivatives for research,
Exclusion Criteria
  • Documented opposition from a patient or his representative (s)
  • Previously established viral load too low.
  • Sample obtained from a sample taken more than 7 days after the appearance of clinical signs of infection.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
arbovirus genome sequencing5 years

Whole genome sequencing of virus extracted of blood samples from patients collected from 1995 to 2024

genetic evolution of arbovirus strains5 years

bioinformatical analysis of the genome of the strains of arbovirus contained in serum samples collected from 1995 to 2024

Secondary Outcome Measures
NameTimeMethod
measurement of the impact of Wolbachia on the virus genetic evolution5 years

comparison of viral genomes extracted from blood samples collected from 1995 to 2024

measurement of the ability of these viruses to replicate in the presence of Wolbachia5 years

infection of cell lines with virus strains isolated and amplified from patient blood samples collected from 1995 to 2024

Trial Locations

Locations (1)

Centre Hospitalier Territorial

🇫🇷

Dumbéa Sur Mer, Nouvelle-Calédonie, France

© Copyright 2025. All Rights Reserved by MedPath